Please Join us for a

HYMPAVZI™
marstacimab-hncq
injection | 150 mg/mL

Speaker Program Event

You're invited to attend a live/virtual HYMPAVZI event!

**Join us for a Pfizer-sponsored presentation of HYMPAVZI,
Help Keep Hemophilia Treatment Administration Simple with Hympavzi (marstacimab-hmcq)**

Date: **Wednesday, February 25, 2026**

Time: **6:00 PM Central Time**

Speaker: **KIM SCHAFER, NP**

Location: **Tycoon**
811 International Parkway 410
Flower Mound, Texas 75022
(972) 537-5720

PLEASE RSVP FOR THIS EVENT BY CONTACTING:

Bethanie Stallings: (405) 474-9407 bethanie.s.stallings@pfizer.com

When you RSVP, please provide your name, email address, organization, and specialty.
Please reference Meeting ID# **INT-0093217**

INDICATIONS AND USAGE

HYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with:

- hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors, or
- hemophilia B (congenital factor IX deficiency) without factor IX inhibitors.

IMPORTANT SAFETY INFORMATION

HYMPAVZI is a tissue factor pathway inhibitor (TFPI) antagonist and may increase the risk of thromboembolic complications. Interrupt HYMPAVZI prophylaxis if diagnostic findings consistent with thromboembolism occur and manage as clinically indicated. If factor VIII or factor IX products are indicated in a patient receiving HYMPAVZI prophylaxis, the minimum effective dose of factor VIII or factor IX according to the product label is recommended.

HYMPAVZI may cause hypersensitivity reactions (including, but not limited to, urticaria and pruritus). If HYMPAVZI-treated patients develop a severe hypersensitivity reaction, advise patients to discontinue HYMPAVZI and seek immediate emergency treatment.

Based on its mechanism of action, **HYMPAVZI may cause fetal harm when administered to a pregnant woman.** Verify that females of reproductive potential are not pregnant prior to initiating HYMPAVZI. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with HYMPAVZI and for 2 months after the last dose.

A serious adverse reaction of peripheral swelling occurred in one patient. Adverse reactions reported in ≥3% of patients treated with HYMPAVZI in clinical trials included injection site reaction (9% of patients); headache (7% of patients); pruritus (3% of patients).

Because late arrivals may be prohibited from participating in the program, please make every effort to arrive by the designated start time. You are expected to remain for the duration of the program

Notice: Pfizer is committed to the appropriate marketing of its products to ensure that interactions with HCPs are professional exchanges designed to benefit patients and enhance the practice of medicine. All Pfizer-sponsored programs are conducted in accordance with PhRMA Code principles to address a bona fide educational need with appropriate attendees in a venue and manner conducive to informational exchange.

State and Federal Employees: State and federal laws and regulations may carry additional restrictions. By attending this event, you confirm that you have obtained any necessary approvals from your employer.

Public Disclosures: Pfizer reports payment and transfer of value data as required by federal and state transparency laws.

State Law Restrictions:
Minnesota: Regardless of where you practice or reside, if you are a Minnesota-licensed practitioner with prescribing privileges, then you may not consume any food or beverage associated with this event.

Vermont: Regardless of where you practice or reside, if you are a Vermont-licensed HCP, you may not consume any food or beverage associated with this event. Additionally, if you are an employee/agent of a Vermont HCP (e.g., PAs, non-prescribing nurses, etc.), regardless of where you practice or reside, you may not consume any food or beverage associated with this event.

Pfizer does not provide or pay for alcohol in connection with any Pfizer-sponsored program.

Please see accompanying **Prescribing Information,**

including **BOXED WARNING**, and Medication Guide.

HYMPAVZI™
marstacimab-hncq
injection | 150 mg/mL

Pfizer